Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

NCT07012980 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Polatuzumab Vedotin
DRUG: Zanubrutinib

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]